Last reviewed · How we verify

Bivalirudin Injection

Hamad Medical Corporation · FDA-approved active Small molecule Quality 5/100

Bivalirudin Injection is a Small molecule drug developed by Hamad Medical Corporation. It is currently FDA-approved. Also known as: anticoagulation.

At a glance

Generic nameBivalirudin Injection
Also known asanticoagulation
SponsorHamad Medical Corporation
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Bivalirudin Injection

What is Bivalirudin Injection?

Bivalirudin Injection is a Small molecule drug developed by Hamad Medical Corporation.

Who makes Bivalirudin Injection?

Bivalirudin Injection is developed and marketed by Hamad Medical Corporation (see full Hamad Medical Corporation pipeline at /company/hamad-medical-corporation).

Is Bivalirudin Injection also known as anything else?

Bivalirudin Injection is also known as anticoagulation.

What development phase is Bivalirudin Injection in?

Bivalirudin Injection is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing